icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL 2017 - European Association for the
Study of the Liver
Amsterdam, The Netherlands. 2017
Back grey_arrow_rt.gif
 
 
 
A Phase 2a Study Evaluating the Multi-dose Activity of ARB-1467 in HBeAg-Positive and -Negative Virally Suppressed Subjects with Hepatitis B
 
 
  Reported by Jules Levin
EASL 2017 April 19-23 Amsterdam Netherlands
 
Adrian Streinu-Cercel1, Ed Gane2, Wendy Cheng3, William Sievert4, Stuart Roberts5, Sang Hoon Ahn6, Yoon Jun Kim7, Kosh Agarwal8, William Symonds9, Patricia Mendez9
 
1Carol Davila University of Medicine and Pharmacy, Prof. Dr. Matei Bals National Institute for Infectious Diseases, Bucharest, Romania; 2Auckland Clinical Studies Limited, Auckland, New Zealand; 3Royal Perth Hospital and Linear Research, Perth, Australia; 4Monash Health, Melbourne, Australia; 5The Alfred, Melbourne, Australia; 6Yonsei University College of Medicine, Seoul, South Korea; 7Seoul National University College of Medicine, Seoul, South Korea; 8King's College Hospital Foundation Trust, London, United Kingdom; 9Arbutus Biopharma Corporation, Burnaby, Canada.

0505171

0505172

0505173

0505174

0505175

0505176

0505177